Effect of ASP2151, a Herpesvirus Helicase-Primase Inhibitor, in a Guinea Pig Model of Genital Herpes
Open Access
- 24 August 2011
- Vol. 16 (9), 7210-7223
- https://doi.org/10.3390/molecules16097210
Abstract
ASP2151 is a herpesvirus helicase-primase inhibitor with antiviral activity against varicella zoster virus and herpes simplex virus types 1 (HSV-1) and 2 (HSV-2). Here, we examined the potency and efficacy of ASP2151 against HSV in vitro and in vivo. We found that ASP2151 was more potent in inhibiting the replication of HSV-1 and HSV-2 in Vero cells in the plaque reduction assay and had greater anti-HSV activity in a guinea pig model of genital herpes than did acyclovir and valacyclovir (VACV), respectively. Oral ASP2151 given from the day of infection reduced peak and overall disease scores in a dose-dependent manner, resulting in complete prevention of symptoms at the dose of 30 mg/kg. The 50% effective dose (ED50) values for ASP2151 and VACV were 0.37 and 68 mg/kg, respectively, indicating that ASP2151 was 184-fold more potent than VACV. When ASP2151 was administered after the onset of symptoms, the disease course of genital herpes was suppressed more effectively than by VACV, with a significant reduction in disease score observed one day after starting ASP2151 at 30 mg/kg, whereas the therapeutic effect of VACV was only evident three days after treatment at the highest dose tested (300 mg/kg). This indicated that ASP2151 possesses a faster onset of action and wider therapeutic time window than VACV. Further, virus shedding from the genital mucosa was significantly reduced with ASP2151 at 10 and 30 mg/kg but not with VACV, even at 300 mg/kg. Taken together, our present findings demonstrated the superior potency and efficacy of ASP2151 against HSV.Keywords
This publication has 41 references indexed in Scilit:
- Potent In Vivo Antiviral Activity of the Herpes Simplex Virus Primase-Helicase Inhibitor BAY 57-1293Antimicrobial Agents and Chemotherapy, 2002
- Daily or Weekly Therapy with Resiquimod (R?848) Reduces Genital Recurrences in Herpes Simplex Virus–Infected Guinea Pigs during and after TreatmentThe Journal of Infectious Diseases, 2001
- Effect of undecylenic acid as a topical microbicide against genital herpes infection in mice and guinea pigsAntiviral Research, 1999
- Herpes Simplex VirusesClinical Infectious Diseases, 1998
- Frequent genital herpes simplex virus 2 shedding in immunocompetent women. Effect of acyclovir treatment.JCI Insight, 1997
- Virologic Characteristics of Subclinical and Symptomatic Genital Herpes InfectionsNew England Journal of Medicine, 1995
- Evaluation of HPMPC therapy for primary and recurrent genital herpes in mice and guinea pigsAntiviral Research, 1993
- Treatment of Recurrent Herpes Simplex Labialis with Oral AcyclovirThe Journal of Infectious Diseases, 1990
- Recurrences after Oral and Genital Herpes Simplex Virus InfectionNew England Journal of Medicine, 1987
- Effect of Acyclovir on Genital Herpes in Guinea PigsThe Journal of Infectious Diseases, 1982